



THE EFFECTIVE
STATISTICIAN
ACADEMY

Mastering study design and strategy with Simulation

Presenters:



Kim Hacquoil

Chief Data Scientific Officer



Jamie Inshaw

Strategic Consulting Team Lead



The Effective Statistician Academy



exploristics
INNOVATIVE ANALYTICS SOLUTIONS

Agenda Outline



Scene Setting: Challenges and Opportunities for simulation



Simulation: What, Why and When?



Simulation Framework and Plans



Where do you get the data from?



Regulators Viewpoint



Communication of Simulations



Efficient Simulations




Example





Scene Setting: Challenges and Opportunities for simulation


Drug development challenges and the value of simulation in trial design to address them



Clinical Development is Hard

Takes a long time


Phase transition durations by disease area



Source: Clinical Development Success Rates and Contributing Factors 2011–2020

Costs a lot


Phase costs by therapeutic area



Source: Product Development with Better Clinical Trials

Unlikely to succeed

Overall likelihood of approval by disease area



Source: Clinical Development Success Rates and Contributing Factors 2011–2020

What are Regulators focusing on?



2021
 Advancing Regulatory Science at FDA:
 FOCUS AREAS OF REGULATORY SCIENCE (FARS)

FDA Strategic Initiative	Focus Area of Regulatory Science	Regulated Product Lifecycle			
		Product Characterization, Manufacturing, and Quality	Non-Clinical Pre-market Evaluation	Clinical Pre-market Evaluation	Post-market Activities
Increasing Choice and Competition through Innovation	Individualized Therapies and Precision Medicine	✓	✓	✓	✓
	Complex Innovative Trial Design	✓	✓	✓	✓
	Microbiome Research	✓	✓	✓	✓
	Novel Foods and Food Ingredients	✓	✓	✓	✓
	Regenerative Medicine	✓	✓	✓	✓
	Advanced Manufacturing	✓	✓	✓	✓
	Increasing Access to Generic Alternatives for Complex Drugs	✓	✓	✓	✓
	Biomarkers	✓	✓	✓	✓
	Novel Technologies to Improve Predictivity of Non-Clinical Studies and Replace, Reduce, and Refine Reliance on Animal Testing	✓	✓	✓	✓
	Model-Informed Product Development	✓	✓	✓	✓
Unleashing the Power of Data	Product Safety Surveillance	✓	✓	✓	✓
	Artificial Intelligence	✓	✓	✓	✓
	Digital Health	✓	✓	✓	✓
	Use of Real-World Evidence to Support Medical Product Development and Regulatory Decision-Making	✓	✓	✓	✓




EUROPEAN MEDICINES AGENCY
 SCIENCE MEDICINES HEALTH

EMA Regulatory Science to 2025

Strategic reflection

Figure 3. Top 5 core recommendations thought to deliver the most significant change - Human



- 9. Foster innovation in clinical trials
- 18. Promote use of high-quality real-world data (RWD) in decision making
- 17. Reinforce patient relevance in evidence generation
- 15. Contribute to HTA's preparedness and downstream decision making for innovative medicines
- 1. Support developments in precision medicine, biomarkers and 'omics

[Focus Areas of Regulatory Science | FDA](#); [EMA Regulatory Science to 2025 \(europa.eu\)](#)

Traditional Statistical Study Support

The Clinical Trial Design Process

1 Target Product Profile

2 Clinical Development Plan

3 Research Questions

4 Study Concept

5 Protocol Synopsis

6 Draft Protocol

7 Final Protocol

Traditional Statistical Study Support

~0.1% of total study cost spent on de-risking

Summary Statistics

Treatment Effects

Sample Size Calculations

Primary Endpoint


Decision Criteria

High Risk Protocol

Simulation Based Approach to Study Design

The Clinical Trial Design Process

- 1 Target Product Profile
- 2 Clinical Development Plan
- 3 Research Questions
- 4 Study Concept
- 5 Protocol Synopsis
- 6 Draft Protocol
- 7 Final Protocol



Pressures on statisticians in clinical trial design and clinical development planning




How does simulation help statisticians overcome these pressures?



How many times have you ignored the fact you will have...


- discrete data?




- missing data?

Case Study		
S1	S2	S3
Gender	GLUCOSE	Age
M	?	65
F	120	71
F	99	?
F	140	52
M	88	?
F	85	63
M	170	68
?	153	80
M	115	59
F	103	?


- baseline in your analysis?



- repeated measurements?



- truncated data?



We make simplifying assumptions when designing studies. But how do we know which we can ignore?
Simulation is of value in simple situations!

What if we aren't in a simple situation?

Multiple endpoints and correlations

Complex decision criteria

Estimands with intercurrent events

Uncertain setting

Exploration of sub populations

Constrained settings e.g rare diseases

Adaptations and decision rules

Recruitment considerations

Benefits of simulation are huge!



Scene Setting: Challenges and Opportunities for simulation

Summary

- Lots of opportunity for statisticians to influence in drug development to help overcome some of the challenges
- Simulation is a key tool that every statistician should have in their toolbox

